We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read moreThe final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more